Page 95 - Hematology_ Basic Principles and Practice ( PDFDrive )

66 Part I Molecular and Cellular Basis of Hematology

the cell. One example of interest is vitamin K epoxide reductase 11. Oldfield CJ, Dunker AK: Intrinsically disordered proteins and intrinsi-
(VKOR), the target of the anticoagulant drug warfarin (see Chapter cally disordered protein regions. Annu Rev Biochem 83:553, 2014. doi:
125). VKOR resides in the endoplasmic reticulum membrane, and 10.1146/annurev-biochem-072711-164947.
catalyzes a key step in the vitamin K cycle: regeneration of vitamin 12. Dyson HJ, Wright PE: Intrinsically unstructured proteins and
K hydroquinone. This compound is a cofactor for the enzyme that their functions. Nat Rev Mol Cell Biol 6:197, 2005. doi: 10.1038/
converts glutamic acid residues in the N-termini of vitamin K– nrm1589.
dependent clotting factors to γ-carboxy glutamate (Gla) residues. 13. Bork P, Holm L, Sander C: The immunoglobulin fold. Structural clas-
This posttranslational modification is required for interaction of sification, sequence patterns and common core. J Mol Biol 242:309,
2+
these proteins with Ca , and thus for their function in coagulation. 1994.
Although the structure of the human enzyme has not been eluci- 14. Teichmann SA, Chothia C: Immunoglobulin superfamily proteins in
dated, the structure of a homologous bacterial protein was recently Caenorhabditis elegans. J Mol Biol 296:1367, 2000.
41
described. In this crystal structure (Fig. 6.6B), the bacterial homo- 15. Chothia C, Jones EY: The molecular structure of cell adhesion molecules.
logue of VKOR is naturally fused to a thioredoxin (Trx)-like domain, Annu Rev Biochem 66:823, 1997.
which supplies reducing equivalents. The core of VKOR structure is 16. Williams AF, Davis SJ, He Q, et al: Structural diversity in domains of
a four-helix bundle embedded in the membrane (transmembrane the immunoglobulin superfamily. Cold Spring Harb Symp Quant Biol
helices TM1–TM4, shown in green), with a fifth transmembrane 54(Pt 2):637, 1989.
helix (TM5) linked to the Trx-like domain on the extracellular 17. Zwick MB, Komori HK, Stanfield RL, et al: The long third
surface (topologically equivalent to the luminal side of ER-resident complementarity-determining region of the heavy chain is important in
mammalian VKOR). The ubiquinone compound has its quinone the activity of the broadly neutralizing anti-human immunodeficiency
ring located near the membrane surface with its isoprenyl tail inter- virus type 1 antibody 2F5. J Virol 78:3155, 2004.
calated into the V-shaped cleft between TM2 and TM3. All the 18. Wang JH, Reinherz EL: The structural basis of alphabeta T-lineage
enzymatically important residues are on or close to the extracellular immune recognition: TCR docking topologies, mechanotransduction,
side of the membrane, adjacent to the Trx-like domain, providing a and co-receptor function. Immunol Rev 250:102, 2012. doi: 10.1111/
41
plausible path for electron transfer. Interestingly, mapping of j.1600-065X.2012.01161.x.
mutations that confer resistance to warfarin onto the bacterial struc- 19. Rudolph MG, Stanfield RL, Wilson IA: How TCRs bind MHCs, pep-
ture reveals striking clustering around the ligand-binding pocket, tides, and coreceptors. Annu Rev Immunol 24:419, 2006.
confirming that it is also the site of warfarin binding. This pocket is 20. Parker MJ, Dempsey CE, Hosszu LL, et al: Topology, sequence evolution
not large enough to accommodate both vitamin K and warfarin, an and folding dynamics of an immunoglobulin domain. Nat Struct Biol
indication that warfarin exerts its inhibitory effect by displacing 5:194, 1998.
vitamin K. 41 21. Boggon TJ, Murray J, Chappuis-Flament S, et al: C-cadherin ectodo-
main structure and implications for cell adhesion mechanisms. Science
296:1308, 2002.
FUTURE DIRECTIONS 22. Jones EY, Davis SJ, Williams AF, et al: Crystal structure at 2.8 A resolu-
tion of a soluble form of the cell adhesion molecule CD2. Nature
In this chapter, we have reviewed basic principles of protein struc- 360:232, 1992.
ture and introduced a few representative protein folds that recur in 23. Wu H, Kwong PD, Hendrickson WA: Dimeric association and
proteins of key importance in hematology. Further examples found segmental variability in the structure of human CD4. Nature 387:527,
throughout the text reflect the value of understanding the structural 1997.
foundations of biologic processes. Structure is key for understand- 24. Yang Y, Jun CD, Liu JH, et al: Structural basis for dimerization of
ing macromolecular function at a mechanistic level, and by exten- ICAM-1 on the cell surface. Mol Cell 14:269, 2004.
sion for understanding pathogenic mutations and mechanisms of 25. Cunningham BA, Hemperly JJ, Murray BA, et al: Neural cell adhesion
drug action. Increasingly powerful structural methods, in particular molecule: structure, immunoglobulin-like domains, cell surface modula-
in cryo-electron microscopy, 42,43 promise to bring ever larger and tion, and alternative RNA splicing. Science 236:799, 1987.
more complicated proteins and macromolecular complexes into 26. Meijers R, Puettmann-Holgado R, Skiniotis G, et al: Structural basis of
focus. Dscam isoform specificity. Nature 449:487, 2007.
27. Sawaya MR, Wojtowicz WM, Andre I, et al: A double S shape provides
the structural basis for the extraordinary binding specificity of Dscam
REFERENCES isoforms. Cell 134:1007, 2008.
28. Taylor SS, Kornev AP: Protein kinases: evolution of dynamic regulatory
1. Walsh C: Posttranslational modification of proteins: expanding nature’s proteins. Trends Biochem Sci 36:65, 2011.
inventory, Englewood, CO, 2006, Roberts and Co. Publishers. 29. Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases.
2. Glozak MA, Sengupta N, Zhang X, et al: Acetylation and deacetylation Cell 141:1117, 2010.
of nonhistone proteins. Gene 363:15, 2005. doi: 10.1016/j.gene.2005.09. 30. Golub TR, McLean T, Stegmaier K, et al: The TEL gene and human
3. Richardson JS: The anatomy and taxonomy of protein structure. Adv leukemia. Biochim Biophys Acta 1288:M7, 1996.
Protein Chem 34:167, 1981. 31. Barreca A, Lasorsa E, Riera L, et al: Anaplastic lymphoma kinase in
4. Kolb VA, Makeyev EV, Sirin AS: Co-translational folding of an eukary- human cancer. J Mol Endocrinol 47:R11, 2011.
otic multidomain protein in a prokaryotic translation system. J Biol 32. Druker BJ: Translation of the Philadelphia chromosome into therapy for
Chem 275:16597, 2000. CML. Blood 112:4808, 2008.
5. Gilbert W: Why genes in pieces? Nature 271:501, 1978. 33. Nagar B, Hantschel O, Young MA, et al: Structural basis for the auto-
6. Liu M, Grigoriev A: Protein domains correlate strongly with exons in inhibition of c-Abl tyrosine kinase. Cell 112:859, 2003.
multiple eukaryotic genomes–evidence of exon shuffling? Trends Genet 34. Nagar B, Hantschel O, Seeliger M, et al: Organization of the SH3-SH2
20:399, 2004. unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell
7. Rossmann MG, Moras D, Olsen KW: Chemical and biological evolution 21:787, 2006.
of nucleotide-binding protein. Nature 250:194, 1974. 35. Hantschel O, Nagar B, Guettler S, et al: A myristoyl/phosphotyrosine
8. Levitt M: Nature of the protein universe. Proc Natl Acad Sci USA switch regulates c-Abl. Cell 112:845, 2003.
106:11079, 2009. 36. Zhang J, Adrián FJ, Jahnke W, et al: Targeting Bcr-Abl by combining
9. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis allosteric with ATP-binding-site inhibitors. Nature 463:501, 2010. doi:
of the human genome. Nature 409:860, 2001. doi: 10.1038/35057062. 10.1038/nature08675.
10. Das R, Baker D: Macromolecular modeling with rosetta. Annu Rev 37. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are
Biochem 77:363, 2008. there? Nat Rev Drug Discov 5:993, 2006. doi: 10.1038/nrd2199.